Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 COMPETITIVE INTELLIGENCE
4.4 MIDDLE EAST AND AFRICA AND REGIONAL PREVALENCE:
4.5 INDUSTRY INSIGHTS
4.6 KEY MARKETING STRATEGIES FOR THE MIDDLE EAST AND AFRICA INSULIN MARKET TYPE 1 & TYPE 2 DIABETES
4.7 MARKETED DRUG ANALYSIS
5 PIPELINE ANALYSIS
6 REGULATORY FRAMEWORK
6.1 REGULATORY FRAMEWORK FOR THE ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.1.1 REGULATORY APPROVAL PROCESS
6.1.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.1.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.1.4 LICENSING AND REGISTRATION
6.1.5 POST-MARKETING SURVEILLANCE
6.1.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.2 REGULATORY FRAMEWORK FOR THE NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.2.1 REGULATORY APPROVAL PROCESS
6.2.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.2.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.2.4 LICENSING AND REGISTRATION
6.2.5 POST-MARKETING SURVEILLANCE
6.2.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.3 REGULATORY FRAMEWORK FOR THE SOUTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.3.1 REGULATORY APPROVAL PROCESS
6.3.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.3.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.3.4 LICENSING AND REGISTRATION
6.3.5 POST-MARKETING SURVEILLANCE
6.3.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.4 REGULATORY FRAMEWORK FOR THE EUROPE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.4.1 REGULATORY APPROVAL PROCESS
6.4.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.4.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.4.4 LICENSING AND REGISTRATION
6.4.5 POST-MARKETING SURVEILLANCE
6.4.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.5 REGULATORY FRAMEWORK FOR THE MIDDLE EAST & AFRICA (MEA) INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.5.1 REGULATORY APPROVAL PROCESS
6.5.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.5.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.5.4 LICENSING AND REGISTRATION
6.5.5 POST-MARKETING SURVEILLANCE
6.5.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF DIABETES
7.1.2 GROWING ADOPTION OF INSULIN THERAPIES FOR TYPE 1 AND TYPE 2 DIABETES
7.1.3 INTEGRATION OF AUTOMATED INSULIN DELIVERY (AID)
7.1.4 INCREASING TECHNOLOGICAL INNOVATIONS FOR INSULIN
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS OF HIGH DOSAGE OF INSULIN
7.2.2 HIGH PRODUCTION AND DEVELOPMENT COSTS ASSOCIATED WITH INSULIN
7.3 OPPORTUNITIES
7.3.1 ADVANCEMENTS IN INSULIN FORMULATION AND DELIVERY TECHNOLOGIES
7.3.2 REVOLUTIONIZING DIABETES MANAGEMENT WITH NEEDLE-FREE INSULIN
7.3.3 INCREASING PHARMACEUTICAL INVESTMENTS AND STRATEGIC COLLABORATIONS
7.4 CHALLENGES
7.4.1 INSULIN ACCESSIBILITY CHALLENGES IN RURAL AND UNDERSERVED REGIONS
7.4.2 LIMITED SHELF LIFE ASSOCIATED WITH ORAL INSULIN
8 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE
8.1 OVERVIEW
8.2 TYPE 2 DIABETES
8.3 TYPE 1 DIABETES
9 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE
9.1 OVERVIEW
9.2 ANALOG INSULIN
9.3 HUMAN INSULIN
9.4 OTHERS
10 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 LONG ACTING INSULIN
10.3 RAPID-ACTING INSULIN
10.4 SHORT ACTING INSULIN
10.5 OTHERS
11 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD
12.1 OVERVIEW
12.2 INSULIN PENS
12.3 VIAL & SYRINGE
12.4 INSULIN PUMPS
12.5 INHALABLE INSULIN
12.6 IMPLANTABLE INSULIN DELIVERY SYSTEMS
13 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT PATIENTS
13.3 GERIATRIC PATIENTS
13.4 PEDIATRIC PATIENTS
14 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE
14.1 OVERVIEW
14.2 BASAL
14.3 BOLUS
14.4 OTHERS
15 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL PHARMACIES
15.3 HOSPITAL PHARMACIES
15.4 ONLINE PHARMACIES
15.5 DIABETES CLINICS & SPECIALTY PHARMACIES
16 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SAUDI ARABIA
16.1.2 SOUTH AFRICA
16.1.3 EGYPT
16.1.4 U.A.E
16.1.5 ISRAEL
16.1.6 KUWAIT
16.1.7 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILES
19.1 NOVO NORDISK A/S
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 SWOT ANALYSIS
19.1.5 PIPELINE PORTFOLIO
19.1.6 RECENT DEVELOPMENT/ NEWS
19.2 LILLY
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 SWOT ANALYSIS
19.2.5 PRODUCT PORTFOLIO
19.2.6 RECENT DEVELOPMENT
19.3 SANOFI
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 SWOT ANALYSIS
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENT
19.4 BIOCON
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 SWOT ANALYSIS
19.4.5 PIPELINE PRODUCT PORTFOLIO
19.4.6 RECENT DEVELOPMENT
19.5 LUPIN
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 SWOT ANALYSIS
19.5.5 PRODUCT PORTFOLIO
19.5.6 RECENT DEVELOPMENT
19.6 ADOCIA
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 SWOT ANALYSIS
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPMENT
19.7 DIASOME PHARMACEUTICALS, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 SWOT ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 MJ BIOPHARM PVT LTD.
19.8.1 COMPANY SNAPSHOT
19.8.2 SWOT ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 NEKTAR
19.9.1 COMPANY SNAPSHOT
19.9.2 SWOT ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT NEWS
19.1 ORAMED
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 SWOT ANALYSIS
19.10.4 PIPELINE PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPMENT
19.11 SCIGEN PTE. LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 SWOT ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 SHANGHAI FOSUN PHARMACEUTICAL（GROUP）CO., LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 SWOT ANALYSIS
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENT
19.13 WOCKHARDT
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 SWOT ANALYSIS
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
20 QUESTIONNAIRE
List of Table
TABLE 1 THE TOP 10 COUNTRIES BY THE NUMBER OF ADULTS WITH DIABETES IN 2021
TABLE 2 DISTRIBUTION OF EXPENDITURE ACROSS REGIONS:
TABLE 3 NUMBER OF ADULTS WITH DIABETES IS EXPECTED TO INCREASE SIGNIFICANTLY IN SEVERAL COUNTRIES:
TABLE 4 REGIONAL DIABETES STATISTICS: PREVALENCE, TREATMENT, AND OUTCOMES
TABLE 5 MIDDLE EAST AND AFRICA CLINICAL TRIAL MARKET FOR ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 6 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE MIDDLE EAST AND AFRICA ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 7 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE MIDDLE EAST AND AFRICA ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 8 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA TYPE 2 DIABETES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA TYPE 1 DIABETES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA ANALOG INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA HUMAN INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA LONG ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA RAPID-ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA SHORT ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA MALE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA FEMALE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA INSULIN PENS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA VIAL & SYRINGE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA INSULIN PUMPS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA INHALABLE INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA IMPLANTABLE INSULIN DELIVERY SYSTEMS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA ADULT PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA GERIATRIC PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA PEDIATRIC PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA BASAL IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA BOLUS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA DIABETES CLINICS & SPECIALTY PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 51 SAUDI ARABIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 SAUDI ARABIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 SAUDI ARABIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 54 SAUDI ARABIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 55 SAUDI ARABIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 56 SAUDI ARABIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 57 SAUDI ARABIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 58 SAUDI ARABIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 59 SOUTH AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 SOUTH AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 SOUTH AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 62 SOUTH AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 63 SOUTH AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 64 SOUTH AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 65 SOUTH AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 66 SOUTH AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 67 EGYPT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 EGYPT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 EGYPT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 70 EGYPT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 71 EGYPT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 72 EGYPT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 73 EGYPT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 74 EGYPT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 75 U.A.E INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 U.A.E INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 U.A.E INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 78 U.A.E INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 79 U.A.E INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 80 U.A.E INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 81 U.A.E INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 82 U.A.E INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 83 ISRAEL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 ISRAEL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 ISRAEL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 86 ISRAEL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 87 ISRAEL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 88 ISRAEL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 89 ISRAEL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 90 ISRAEL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 91 KUWAIT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 KUWAIT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 KUWAIT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 94 KUWAIT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 95 KUWAIT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 96 KUWAIT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 97 KUWAIT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 98 KUWAIT INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 99 REST OF MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 REST OF MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 REST OF MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 102 REST OF MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 103 REST OF MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 104 REST OF MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 105 REST OF MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 106 REST OF MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SEGMENTATION
FIGURE 10 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE
FIGURE 11 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING PREVALENCE OF DIABETES IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 TYPE 2 DIABETES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 15 TOP 10 COUNTRIES BY THE NUMBER OF ADULTS WITH DIABETES IN 2021
FIGURE 16 MIDDLE EAST AND AFRICA HEALTHCARE EXPENDITURE FOR DIABETES
FIGURE 17 NUMBER OF PEOPLE WITH DIABETES IN 2045 (MILLIONS)
FIGURE 18 DROC ANALYSIS
FIGURE 19 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, 2024
FIGURE 20 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 21 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, CAGR (2025-2032)
FIGURE 22 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, 2024
FIGURE 24 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, 2025 TO 2032 (USD THOUSAND)
FIGURE 25 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, CAGR (2025-2032)
FIGURE 26 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, 2024
FIGURE 28 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 29 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, CAGR (2025-2032)
FIGURE 30 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, 2024
FIGURE 32 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 33 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, CAGR (2025-2032)
FIGURE 34 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, 2024
FIGURE 36 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, 2025 TO 2032 (USD THOUSAND)
FIGURE 37 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, CAGR (2025-2032)
FIGURE 38 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, 2024
FIGURE 40 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, 2025 TO 2032 (USD THOUSAND)
FIGURE 41 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, CAGR (2025-2032)
FIGURE 42 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, 2024
FIGURE 44 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, 2025 TO 2032 (USD THOUSAND)
FIGURE 45 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, CAGR (2025-2032)
FIGURE 46 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, 2024
FIGURE 48 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 49 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 50 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SNAPSHOT (2024)
FIGURE 52 MIDDLE EAST AND AFRICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY SHARE 2024 (%)
